Molecular Formula | C46H80N2O13 |
Molar Mass | 869.15 |
Density | 1.18±0.1 g/cm3(Predicted) |
Melting Point | >97°C (dec.) |
Boling Point | 926.6±65.0 °C(Predicted) |
Specific Rotation(α) | D23 +12.75° (c = 0.010004 in CHCl3, 5 cm) |
Flash Point | 514.2°C |
Solubility | DMSO 100 mg/mL Water 8 mg/mL Ethanol <1 mg/mL |
Vapor Presure | 0mmHg at 25°C |
Appearance | White to white-like powder or crystal |
Color | White to Off-White |
pKa | pKa (66% DMF): 7.4, 8.5(at 25℃) |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
Refractive Index | 1.545 |
MDL | MFCD00864842 |
Physical and Chemical Properties | White or white powder humidity: ≤ 5.0% |
Use | Mainly used for the treatment of pleuropneumonia, Actinobacillus, Pasteurella and mycoplasma infection caused |
In vitro study | Tilmicosin inhibits the growth of Pasteusiella multocidae, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Streptococcus suis, Actinomyces pyogenes, and certain other bacteria at doses of 6.25 μg/ml or less. In general, the MIC against Gram-negative enteric bacilli is greater than 50 μg/ml. Tilmicosin decreases SOD and GPX activity in the heart. |
In vivo study | After subcutaneous injection, the elimination of tilmicosin from serum and emulsion was relatively slow, with t1/2βs 9.3 and 41.4 hours, respectively. The apparent volume of distribution of Tlmicosin is greater than 1 liter/kg. After subcutaneous injection of 10 mg/kg, the peak concentration of tilmicosin in plasma was 1.56 μg/ml after 6.39 hours. Tilmicosin is widely secreted into the milk, reaching a maximum concentration of 11.6 μg/ml, and the ACC milk/ACC serum ratio is approximately 12:1. After 11 days of single subcutaneous administration, Tilmicosin was detectable in milk. |
WGK Germany | 3 |
HS Code | 29419090 |